Stock PVCT PROVECTUS BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Delayed OTC Markets
Other stock markets
 20:59:08 27/06/2024 BST 		5-day change 1st Jan Change
0.135 USD -9.01% Intraday chart for Provectus Biopharmaceuticals, Inc. -9.03% +40.62%
05-21 Provectus Biopharmaceuticals, Inc. Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting CI
05-14 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
AQ
Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
AQ
Provectus Biopharmaceuticals, Inc. Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
CI
Provectus: Q1 Earnings Snapshot
AQ
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
AQ
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
AQ
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
AQ
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose
CI
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
AQ
Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President
CI
Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer
CI
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
AQ
Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
AQ
Provectus Biopharmaceuticals, Inc. Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
CI
Provectus Biopharmaceuticals, Inc. Announces Management Changes
CI
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
AQ
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PVCT Stock
  4. News Provectus Biopharmaceuticals, Inc.